Michel Sebastian, Schneider Christian, Ius Fabio, Welte Tobias, Gottlieb Jens, Kneidinger Nikolaus
Department of Cardiac Surgery, LMU Hospital Munich, and Munich Heart Alliance, German Center for Cardiovascular Research (DZHK), Munich, Germany; Comprehensive Pneumology Center Munich, German Center for Lung Research (DZL), Munich, Germany; Division for Thoracic Surgery, LMU Hospital Munich, Germany; Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Gemany; Biomedical Research in Endstage & Obstructive Lung Disease Hannover (BREATH),German Center for Lung Research (DZL), Hannover, Germany; Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Germany; Medical Clinic and Polyclinic V, Pneumology, LMU Hospital Munich, and Division of Pulmonology, Department of Internal Medicine, Medical University of Graz, Austria.
Dtsch Arztebl Int. 2025 Jan 24;122(2):43-48. doi: 10.3238/arztebl.m2024.0232.
Lung transplantation is the treatment of choice for end-stage nonmalignant lung disease. It has become a routine procedure through advances in donor lung preservation, extracorporeal membrane oxygenation, immunosuppression, intensive care medicine, and follow-up care.
This review is based on publications about lung transplantation that were retrieved by a selective literature search, and on the procedures and experience of two large-volume lung transplantation centers.
The mean survival time after lung transplantation is six years, which is the shortest after the transplantation of any solid organ. Chronic graft dysfunction is present in 41% of patients at five years and is the main cause of death after lung transplantation, followed by infection and cancer.
Despite all the advances in lung transplantation, acute and-above all-chronic graft dysfunction still pose a major challenge for large-volume transplantation centers. Immunosuppression that is individually tailored to prevent both graft rejection and infection is important for these patients' longterm survival. Xenotransplantation and so-called lung bioengineering may become available in the future as alternatives to allotransplantation.
肺移植是终末期非恶性肺部疾病的首选治疗方法。通过供肺保存、体外膜肺氧合、免疫抑制、重症医学及后续护理等方面的进展,肺移植已成为一种常规手术。
本综述基于通过选择性文献检索获取的有关肺移植的出版物,以及两个大型肺移植中心的手术和经验。
肺移植后的平均生存时间为6年,这是所有实体器官移植后最短的。41%的患者在5年后出现慢性移植物功能障碍,这是肺移植后死亡的主要原因,其次是感染和癌症。
尽管肺移植取得了所有进展,但急性尤其是慢性移植物功能障碍仍然是大型移植中心面临的重大挑战。为预防移植物排斥和感染而进行个体化调整的免疫抑制对这些患者的长期生存至关重要。异种移植和所谓的肺生物工程未来可能成为同种异体移植的替代方法。